Grants Search Results

This year, neuroblastoma will account for approximately 15% of cancer-related deaths in children. Despite recent advances in treating high-risk neuroblastoma, nearly half of patients will relapse with no curative treatments. Thus, safe and effective treatments are urgently needed. Using recently developed tools to find new therapy targets at a large scale, Dr. Mabe and colleagues understand that neuroblastoma tumors require polycomb repressive complex 1 (PRC1). Dr. Mabe and colleagues will identify that a new class of drugs that blocks PRC1 activity can reduce neuroblastoma tumor growth. To determine the exact mechanism by which these drugs reduce neuroblastoma growth, Dr. Mabe's lab will apply sequencing technologies to assess how PRC1 changes the neuroblastoma tumors to become less like a cancer cell and more like nerve cells.